Related Experiment Video
Updated: May 26, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Mean platelet volume has a prognostic value in patients with coronary artery ectasia
Ercan Varol1, Bayram Ali Uysal, Abdullah Dogan
1Department of Cardiology, Suleyman Demirel University, Isparta, Turkey. drercanvarol@yahoo.com
Insights
Mean platelet volume (MPV) is a significant predictor of major adverse cardiac events (MACEs) in patients with coronary artery ectasia (CAE). Higher MPV levels indicate a greater risk of MACEs in this patient group.
Area of Science:
- Cardiology
- Hematology
Background:
- Coronary artery ectasia (CAE) is a condition affecting coronary arteries.
- Identifying prognostic markers for CAE is crucial for patient management.
Purpose of the Study:
- To investigate the prognostic role of mean platelet volume (MPV) in patients diagnosed with coronary artery ectasia (CAE).
Main Methods:
- A cohort of 258 patients with CAE was screened for baseline MPV values.
- Patients were followed for a mean of 49 months for major adverse cardiac events (MACEs).
- MACEs included cardiac death, myocardial infarction, rehospitalization, and readmission for chest pain.
Main Results:
- Mean platelet volume (MPV) was significantly higher in CAE patients who experienced MACEs compared to those who did not (9.5 ± 1.2 fL vs. 8.9 ± 1.1 fL, P = .002).
- The rate of MACEs was substantially higher in CAE patients with MPV >9 fL than in those with MPV ≤9 fL (33% vs. 15%, P = .001).
Conclusions:
- Mean platelet volume (MPV) demonstrates a significant prognostic value for predicting major adverse cardiac events (MACEs) in patients with coronary artery ectasia (CAE).
- Elevated MPV levels may serve as a valuable biomarker for risk stratification in CAE patients.
Abstract:
The aim of this study was to investigate the prognostic role of mean platelet volume (MPV) in patients with coronary artery ectasia (CAE). The baseline MPV values of 258 patients with CAE were screened. The mean time of follow-up was 49 ± 21 months for major adverse cardiac events (MACEs) defined as the combination of cardiac death, nonfatal myocardial infarction (MI), rehospitalization due to cardiac disorders, and readmission due to chest pain. During follow-up period, 63 (24%) MACEs developed. There were 4 (2%) cardiovascular deaths, 0 nonfatal MI, 14 (5%) rehospitalization, and 45 (17%) readmission. Mean platelet volume values were significantly higher in patients with CAE with MACEs than in patients with CAE without MACEs (9.5 ± 1.2 fL vs 8.9 ± 1.1 fL, respectively, P = .002). The rate of MACE was higher in CAE patients with MPV of >9 fL than those with MVP of ≤9 fL (33% vs. 15%, P = .001). Mean platelet volume has a prognostic value for MACEs in patients with CAE.
